Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Change in Expanded Timed Get-Up-and-Go is Associated with the Expanded Disability Status Scale and Timed 25-Foot Walk in the New York State Multiple Sclerosis Consortium
Multiple Sclerosis
P15 - Poster Session 15 (12:00 PM-1:00 PM)
9-018
We have previously identified that the Expanded Timed Get-Up-and-Go (ETGUG) is a sensitive measure for predicting falls. Our objective in this study was to evaluate the correlations of absolute change of ETGUG, Expanded Disability Status Scale (EDSS) and Timed 25-Foot Walk (T25FW) in a longitudinal sample.
Assessing disability in persons with multiple sclerosis (PwMS) is a constant challenge. Common disability measures include the EDSS and the T25FW, but these constructs have significant limitations, particularly at the ends of the disability spectrum. It is therefore important to identify measures that can better assess and monitor disability progression in PwMS.
Participants in this study are part of the New York State Multiple Sclerosis Consortium (NYSMSC), a 23-year longitudinal registry from clinic centers throughout New York State. Participants with available data on the ETGUG, T25FW and EDSS on two visits were selected for this study (n=94). Paired sample t-tests were carried out to determine significant differences between baseline and follow-up. Absolute change from baseline and follow-up of ETGUG, T25FW and EDSS were reported and correlations were analyzed by Pearson correlations.
The average age for PwMS in our study was 57.0 years (SD=10.8). The majority was female (78.7%), with a mean duration between baseline and follow-up of 25.6±10.9 months. Mean ETGUG scores showed a modest (non-significant [p=.106]) improvement with mean scores of 23.0±9.7 seconds at baseline and 21.7±10.8 seconds at follow-up. Baseline ETGUG scores were highly correlated with both EDSS and T25FW (r=.70, r=.84, respectively). Absolute change in ETGUG scores were significantly correlated with absolute change in both T25FW (r=.74) and EDSS and (r=.42).
Change in ETGUG is significantly associated with change in EDSS and T25FW. Further studies are ongoing to assess the reliability and validity of the ETGUG in predicting disability worsening in PwMS.
Authors/Disclosures
Bianca Weinstock-Guttman, MD (Department of Neurology, University At Buffalo)
PRESENTER 		Dr. Weinstock-Guttman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis . Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genzyme &Sanofi. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen . Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Weinstock-Guttman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Janssen. Dr. Weinstock-Guttman has received personal compensation in the range of $0-$499 for serving as a Reviewer with NIH.
Katelyn S. Kavak (Jacobs MS Treatment and Research Center) Ms. Kavak has nothing to disclose.
Natasha Qutab, MD Dr. Qutab has nothing to disclose.
Osman Ozel, MD (Houston Methodist Hospital) Dr. Ozel has nothing to disclose.
No disclosure on file
Caila B. Vaughn, PhD (UB Neurology) No disclosure on file